Omeros

Xencor Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.
  • Total revenue for the third quarter ended September 30, 2023 was $59.2 million, compared to $27.3 million for the same period in 2022.
  • Decreased net loss in the third quarter of 2023 compared to 2022 is primarily due to additional income earned.
  • ET (1:30 p.m. PT) to discuss the third quarter 2023 financial results and provide a corporate update.

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Retrieved on: 
Monday, November 6, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes.
  • Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
  • For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events .
  • To access the live conference call via phone, participants must register at this link to receive a unique PIN.

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023

Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
  • In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics.
  • “We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology.

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Retrieved on: 
Monday, October 16, 2023

Topline results show that narsoplimab did not achieve statistically significant improvement over placebo.

Key Points: 
  • Topline results show that narsoplimab did not achieve statistically significant improvement over placebo.
  • The UPE reduction in the placebo group was markedly greater than that reported in trials of other agents in IgA nephropathy.
  • Based on the absence of statistical significance and as previously agreed with FDA, Omeros will not submit an application for approval of narsoplimab in this indication and will discontinue the ARTEMIS-IGAN clinical trial.
  • “We want to thank all the patients and investigators who participated in the trial,” said Gregory A. Demopulos, M.D, chairman and chief executive officer of Omeros.

Omeros Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

“Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Key Points: 
  • “Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.
  • Total costs and expenses for the second quarter of 2023 were $40.9 million compared to $37.4 million for the second quarter of 2022.
  • Interest expense during the second quarter of 2023 was $7.9 million compared to $4.9 million during the prior year quarter.
  • During the second quarter of 2023, we earned $4.5 million in interest and other income compared to $0.7 million in the prior year quarter.

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

Retrieved on: 
Friday, August 4, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens.
  • Omeros management will host a conference call and webcast that same day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
  • For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events .
  • To access the live conference call via phone, participants must register at this link to receive a unique PIN.

Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

Retrieved on: 
Thursday, May 4, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes.
  • Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
  • To access the live conference call via phone, please dial (800) 715-9871 from the United States and Canada or (646) 307-1963 internationally and ask to be placed into the Omeros earnings call.
  • For online access to the live or subsequently archived webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events .

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Tuesday, April 25, 2023

To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.

Key Points: 
  • To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.
  • This single-arm, open-label clinical trial is evaluating the effect of once-monthly subcutaneous administration of OMS906 in patients with PNH.
  • OMS906 is Omeros’ lead investigational humanized monoclonal antibody targeting MASP-3, the key and most upstream activator of the alternative pathway of complement.
  • “We are excited by the data resulting from this trial of treatment-naïve patients,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023

Net loss from continuing operations for the fourth quarter of 2022 was $46.0 million, or $0.73 cents per share.

Key Points: 
  • Net loss from continuing operations for the fourth quarter of 2022 was $46.0 million, or $0.73 cents per share.
  • During the fourth quarter of 2022, we earned royalties of $17.9 million on $35.8 million of Rayner sales of OMIDRIA.
  • Total costs and expenses for the fourth quarter of 2022 were $40.1 million compared to $50.8 million for the third quarter of 2022.
  • Interest expense during the fourth quarter of 2022 was $7.9 million, an increase of $3.0 million from the third quarter of 2022.

Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank

Retrieved on: 
Friday, March 10, 2023

Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
  • Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022.
  • Omeros does not have any assets on deposit with Silicon Valley Bank, nor does the company maintain any other financial relationship with the bank or its affiliated entities.